The PRECISION PREDICT project, led by Nicolas Girard and Irène Buvat at Institut Curie, aims to improve clinical decision-making for NSCLC patients treated with Tyrosine Kinase Inhibitors (TKIs). The project, fully developed and conducted by the Curie team, benefits from COALA’s support for the validation cohort, providing access to collaborative datasets across the network.

The team developed a three-factor model integrating patient, tumor, and treatment characteristics to guide therapy selection and optimize outcomes. The results were presented by Fanny Orlhac at the EANM 2025 Annual Congress (October 4–8, 2025) and the corresponding abstract is published in EANM Innovation (Volume 1, Supplement, September 2025, OP-173).

This work demonstrates the potential of combining computational and clinical data to support personalized treatment strategies in lung cancer.